Abstract P1-01-10: Positron emission mammography in assessment of the clinicopathological characteristics of breast cancers

2020 ◽  
Author(s):  
Jun Ito ◽  
Toshihiko Sato
Keyword(s):  
Clinicopathological Characteristics ◽  
Breast Cancers ◽  
Positron Emission Mammography ◽  
Positron Emission

scholarly journals Positron Emission Mammography: High-Resolution Biochemical Breast Imaging

2005 ◽  
Vol 4 (1) ◽  
pp. 55-60 ◽  
Author(s):  
Irving N. Weinberg ◽  
David Beylin ◽  
Valera Zavarzin ◽  
Steve Yarnall ◽  
Pavel Y. Stepanov ◽  
...  
Keyword(s):  
Spatial Resolution ◽  
Breast Imaging ◽  
Signal To Noise Ratio ◽  
High Sensitivity ◽  
High Signal ◽  
Breast Cancers ◽  
Positron Emission Mammography ◽  
Positron Emission ◽  
Ductal Hyperplasia ◽  
Intraductal Cancer

Positron emission mammography (PEM) provides images of biochemical activity in the breast with spatial resolution matching individual ducts (1.5 mm full-width at half-maximum). This spatial resolution, supported by count efficiency that results in high signal-to-noise ratio, allows confident visualization of intraductal as well as invasive breast cancers. Clinical trials with a full-breast PEM device have shown high clinical accuracy in characterizing lesions identified as suspicious on the basis of conventional imaging or physical examination (sensitivity 93%, specificity 83%, area under the ROC curve of 0.93), with high sensitivity preserved (91%) for intraductal cancers. Increased sensitivity did not come at a cost of reduced specificity. Considering that intraductal cancer represents more than 30% of reported cancers, and is the form of cancer with the highest probability of achieving surgical cure, it is likely that the use of PEM will complement anatomic imaging modalities in the areas of surgical planning, high-risk monitoring, and minimally invasive therapy. The quantitative nature of PET promises to assist researchers interested studying the response of putative cancer precursors ( e.g., atypical ductal hyperplasia) to candidate prevention agents.

Positron emission mammography in the diagnosis of breast cancer

2016 ◽  
Vol 55 (01) ◽  
pp. 15-20 ◽  
Author(s):  
J. Farahati ◽  
A. G. Müller ◽  
E. Gillman ◽  
M. Hentschel ◽  
F. H. H. Müller
Keyword(s):  
Breast Cancer ◽  
High Specificity ◽  
Diagnostic Value ◽  
Glandular Tissue ◽  
Breast Cancer Patients ◽  
Malignant Tumours ◽  
Benign Lesions ◽  
Interventional Study ◽  
Positron Emission Mammography ◽  
Positron Emission

SummaryAim: To evaluate the diagnostic value (sensitivity, specificity) of positron emission mammography (PEM) in a single site non-interventional study using the maximum PEM uptake value (PUVmax). Patients, methods: In a singlesite, non-interventional study, 108 patients (107 women, 1 man) with a total of 151 suspected lesions were scanned with a PEM Flex Solo II (Naviscan) at 90 min p.i. with 3.5 MBq 18F-FDG per kg of body weight. In this ROI(region of interest)-based analysis, maximum PEM uptake value (PUV) was determined in lesions, tumours (PUVmaxtumour), benign lesions (PUVmaxnormal breast) and also in healthy tissues on the contralateral side (PUVmaxcontralateral breast). These values were compared and contrasted. In addition, the ratios of PUVmaxtumour / PUVmaxcontralateral breast and PUVmaxnormal breast / PUVmaxcontralateral breast were compared. The image data were interpreted independently by two experienced nuclear medicine physicians and compared with histology in cases of suspected carcinoma. Results: Based on a criteria of PUV>1.9, 31 out of 151 lesions in the patient cohort were found to be malignant (21%). A mean PUVmaxtumour of 3.78 ± 2.47 was identified in malignant tumours, while a mean PUVmaxnormal breast of 1.17 ± 0.37 was reported in the glandular tissue of the healthy breast, with the difference being statistically significant (p < 0.001). Similarly, the mean ratio between tumour and healthy glandular tissue in breast cancer patients (3.15 ± 1.58) was found to be significantly higher than the ratio for benign lesions (1.17 ± 0.41, p < 0.001). Conclusion: PEM is capable of differentiating breast tumours from benign lesions with 100% sensitivity along with a high specificity of 96%, when a threshold of PUVmax >1.9 is applied.

scholarly journals Clinical practice guidelines for high-resolution breast PET, 2019 edition

2021 ◽  
Vol 35 (3) ◽  
pp. 406-414
Author(s):  
Yoko Satoh ◽  
Masami Kawamoto ◽  
Kazunori Kubota ◽  
Koji Murakami ◽  
Makoto Hosono ◽  
...  
Keyword(s):  
High Resolution ◽  
Practice Guidelines ◽  
Breast Imaging ◽  
Japanese Society ◽  
Insurance Coverage ◽  
Whole Body ◽  
Positron Emission Mammography ◽  
Dedicated Breast Pet ◽  
Positron Emission ◽  
Different Types

AbstractBreast positron emission tomography (PET) has had insurance coverage when performed with conventional whole-body PET in Japan since 2013. Together with whole-body PET, accurate examination of breast cancer and diagnosis of metastatic disease are possible, and are expected to contribute significantly to its treatment planning. To facilitate a safer, smoother, and more appropriate examination, the Japanese Society of Nuclear Medicine published the first edition of practice guidelines for high-resolution breast PET in 2013. Subsequently, new types of breast PET have been developed and their clinical usefulness clarified. Therefore, the guidelines for breast PET were revised in 2019. This article updates readers as to what is new in the second edition. This edition supports two different types of breast PET depending on the placement of the detector: the opposite-type (positron emission mammography; PEM) and the ring-shaped type (dedicated breast PET; dbPET), providing an overview of these scanners and appropriate imaging methods, their clinical applications, and future prospects. The name “dedicated breast PET” from the first edition is widely used to refer to ring-shaped type breast PET. In this edition, “breast PET” has been defined as a term that refers to both opposite- and ring-shaped devices. Up-to-date breast PET practice guidelines would help provide useful information for evidence-based breast imaging.

Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation.

1993 ◽  
Vol 11 (11) ◽  
pp. 2101-2111 ◽  
Author(s):  
R L Wahl ◽  
K Zasadny ◽  
M Helvie ◽  
G D Hutchins ◽  
B Weber ◽  
...  
Keyword(s):  
Glucose Metabolism ◽  
Tumor Size ◽  
Fdg Pet ◽  
Tumor Diameter ◽  
Breast Cancers ◽  
Tumor Uptake ◽  
Influx Rate ◽  
Metabolic Monitoring ◽  
Positron Emission ◽  
Pet Scans

PURPOSE We assessed the feasibility of noninvasive metabolic monitoring of cancer chemohormonotherapy using sequential quantitative positron emission tomographic (PET) scans of tumor glucose metabolism with the glucose analog 2-[18F]-fluoro-2-deoxy-D-glucose (FDG). PATIENTS AND METHODS Eleven women with newly diagnosed primary breast cancers larger than 3 cm in diameter beginning a chemohormonotherapy program underwent a baseline and four follow-up quantitative PET scans during the first three cycles of treatment (days 0 to 63). Tumor response was sequentially determined clinically, radiographically, and then pathologically after nine treatment cycles. RESULTS Eight patients had partial or complete pathologic responses. Their maximal tumor uptake of FDG assessed by PET decreased promptly with treatment to the following: day 8, 78 +/- 9.2% (P < .03); day 21, 68.1 +/- 7.5% (P < .025); day 42, 60 +/- 5.1% (P < .001); day 63, 52.4 +/- 4.4% (P < .0001) of the basal values. Tumor diameter did not decrease significantly during this period through 63 days. Prompt decreases in the FDG influx rate (K) from basal levels (from .019 to .014 mL/cm3/min) after 8 days of treatment (P < .02) and in the estimated rate of FDG phosphorylation to FDG-6-phosphate (k3) from .055 to .038 min-1 after 8 days of treatment (P < .02) to .029 +/- .004 min-1 at 21 days) (P < .02) were observed. Three nonresponding patients had no significant decrease in tumor uptake of FDG (81 +/- 18% of basal value), influx rate (.015 to .012 mL/cm3/min), or tumor size (81 +/- 12% of basal diameter) comparing basal versus 63-day posttreatment values. CONCLUSION Quantitative FDG PET scans of primary breast cancers showed a rapid and significant decrease in tumor glucose metabolism after effective treatment was initiated, with the reduction in metabolism antedating any decrement in tumor size. No significant decrease in FDG uptake (SUV) after three cycles of treatment was observed in the nonresponding patients. FDG PET scanning has substantial promise as an early noninvasive metabolic marker of the efficacy of cancer treatment.

Sign in / Sign up

Export Citation Format

Share Document